- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Ryan Huey: Expansion of Patient Support, Care Key to Improve Value-Based Oncology
There are various areas across different patient care and support perspectives that offer opportunities to improve value-based care in oncology, said Ryan Huey, MD, gastrointestinal medical oncologist at MD Anderson Cancer Center in Houston, Texas.
Patient services across various perspectives such as direct patient care and patient support are areas that health systems can expand upon to improve value-based oncology care, said Ryan Huey, MD gastrointestinal medical oncologist at MD Anderson Cancer Center in Houston, Texas.
Transcript
What actions can health systems take to improve value-based oncology care within their organizations?
I think from a direct patient care perspective, there's a role to think about the expanded use of telemedicine and also potentially, chemotherapy even at home, or certainly closer to where a patient lives as opposed to in a traditional infusion suite or a hospital. From a support services perspective, there's a role to expand a lot of services. Some of these were described in the Oncology Care Model such as social work or nutritional support or navigation, physical therapy, palliative care; these are things that are not traditionally reimbursed in a fee-for-service environment, however, can lead to improved outcomes for patients or reduced costs throughout the patient journey. So, this is an excellent way to also think about expanding the use of value-based care in the oncology space
Driving Value via Outcomes-Based Pricing and EHR Interoperability: Tyler Sandahl, PharmD
July 7th 2025Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, discussed the complexities of alternative payment models for chimeric antigen receptor T-cell and bispecific therapies and the need for improved data sharing in cancer care.
Read More
Targeting the Root of gMG With Inebilizumab: A Q&A With Richard Nowak, MD, MS
June 24th 2025In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant improvements in patient- and physician-assessed outcomes, as well as longer-term implications and future areas of investigation.
Read More
